Abstract
The outcome of the early benefit assessment process (according to §35a SGB V) is crucial for the successful launch and commercialization of pharmaceuticals in Germany. We aim to analyze the change in reimbursement price after early benefit assessment for the first non-orphan evaluation of a drug.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
